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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
Thyroxine and tri-iodothyronine are essential for normal organ growth, 
development and function. These hormones regulate the basal metabolic rate of all 
cells, including hepatocytes, and thereby modulate hepatic function. The liver plays 
an important role in thyroid hormone metabolism being involved in their 
conjugation, excretion, peripheral deiodination and in the synthesis of thyroid 
binding globulin. Thyroid dysfunction may perturb liver function, liver disease 
modulates thyroid hormone metabolism, and a variety of systemic diseases affect 
both organs. 
 Although almost all patients with liver disease are clinically euthyroid, 
some abnormalities in the circulating hormone concentrations have been shown in 
previous studies. These data, however, are still controversial as the discrepant 
results reported may depend on the different analytical methods used as well as 
different groups of patients investigated. 
 The total and free thyroxine have been reported as normal, increased or 
decreased in various liver diseases; abnormalities in thyroxine binding globulin 
1
serum concentration and a reduced thyroid hormone binding capacity, perhaps 
because of a hypothetical circulating inhibitor, have also been reported. Moreover, 
total and free triiodothyronine concentration are often decreased, sometimes 
profoundly and their levels correlate well with severity of liver dysfunction. In 
order to further evaluate the thyroid function in liver disease, this study measures 
T3, T4, FT3, FT4 serum levels in patients with chronic liver disease    
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AIM  OF THE 
       STUDY                   
 
 
 
 
    
 
 
 
 
 
     AIM  OF THE STUDY 
 
 
To evaluate the following : 
1. thyroid functions in patients with chronic liver disease 
2. To assess the severity of liver dysfunction in relation with interpretation of 
thyroid functions 
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        OF  
LITERATURE  
 
 
 
 
 
 
  
 
REVIEW OF LITERATURE 
 
 
The relationship between the thyroid gland and the liver 
 
Thyroxine and tri-iodothyronine are essential for normal organ growth, 
development and function. These hormones regulate the basal metabolic rate of all 
cells, including hepatocytes, and thereby modulate hepatic function; the liver in 
turn metabolizes the thyroid hormones and regulates their systemic endocrine 
effects. Thyroid dysfunction may perturb liver function, liver disease modulates 
thyroid hormone metabolism, and a variety of systemic diseases affect both organs 
Intracellular signaling     
The thyroid gland secretes two iodine containing amine hormones derived 
from the amino acid tyrosine, L-thyroxine (T4) and 3,5,3'-L-tri-iodothyronine (T3). 
Free T3 and T4 enter all cells through the plasma membrane and bind to a nuclear 
T3 receptor. 
The thyroid receptor is part of the nuclear super family group of receptors 
(retinoic acid, retinoid X, vitamin D and peroxisome proliferator receptor).These 
receptors all possess six similar domains, two of which are a ligand-binding region 
and a central region that constitutively binds to DNA.  
4 
The main function of the thyroid receptor is to act as a ligand-activated 
transcription factor that regulates target gene expression directly through DNA 
response elements (thyroid response elements). 
However, an important property of these receptors is that they bind thyroid 
response elements constitutively, independent of ligand occupancy. 
REGULATION OF THYROID HORMONES 
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Thyroid hormone metabolism 
The thyroid gland secretes 110 nmol of thyroxine and 10 nmol of tri-
iodothyronine each day. Tri-iodothyronine has a ten times greater affinity and ten 
times greater efficacy than thyroxine for the nuclear receptor, thus even though 
thyroxine is quantitatively secreted at much higher levels, it should be regarded as a 
pro-hormone that requires deiodination and conversion to T3 to become 
biologically active. There are three groups of enzymes that regulate thyroid 
hormone metabolism, forming part of the iodothyronine seleno-deiodinase enzyme 
system. They are responsible for the activation of T4 to T3, inactivation of T4 to rT3 
and the conversion of rT3 and T3 to T2 
 
Peripheral conversion of thyroid hormones 
The conversion of T4 to T3 in extra thyroidal tissue occurs through a rapidly 
equilibrating pool. The type 1 deiodinase is mainly found in the liver and kidney, 
and accounts for approximately 30–40% of extra thyroidal production of T3 (12 
nmol). The type 2 deiodinase is found in the pituitary, the CNS, and skeletal 
muscle and contributes 60–70% of the extra thyroidal production of T3 (30 nmol). 
Although this enzyme system performs similar actions to the type 1 de-iodinase 
activity group of enzymes, its kinetics, regulation and susceptibility to 
propylthiouracil are different. 
6
 Although both the type 1 de-iodinase and type2 de-iodinase system can also 
inactivate T4 and T3, the major inactivator is the type 3 deiodinase system, which 
primarily exhibits inner-ring deiodination (unlike the other systems). It is found in 
the liver, skin and CNS, where it catalyses the conversion of T4 to rT3 and T3 to T2, 
both inactive metabolites; it also converts rT3 to rT2. This enzyme system is also 
expressed in placenta, where it protects the fetus from maternal thyroid hormones. 
              
 In addition to the central role in deiodination to activate and deactivate 
thyroid hormones, the liver performs specific functions relating to thyroid hormone 
transport and metabolism.  
 
The liver extracts 5–10% of plasma T4 during a single passage, as shown by  
studies using [131I]T4. This value is much higher than can be accounted for by the  
amount of free T4 delivered to the liver, indicating that a substantial amount of  
bound  T4 is available for uptake. An active stereo-specific transport mechanism has 
 been identified for transporting T4 and T3 across the hepatocyte membrane. The  
intracellular concentrations of the free hormone are higher than the plasma levels, 
 and the process is energy-dependent 
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                 The liver synthesizes a number of plasma proteins that bind the  
lipophilic thyroid hormones and thereby provide a large, rapidly exchangeable pool  
of circulating hormone. The thyroid hormones are >99% bound to thyroxine- 
binding globulin, thyroxine-binding prealbumin and albumin in plasma. The free  
hormone component within plasma is in equilibrium with the protein-bound  
hormone, and it is this free fraction which accounts for the hormone's biological  
activities. The plasma concentrations of free T4 and T3 are at a steady 
concentration, so that the tissues are exposed to the same concentrations of the free 
hormone. However, the free hormone concentrations in different tissues vary 
according to the transport and deiodinase activity within specific tissues. 
 
Thus tissue thyroid status depends not only on thyroxine secretion but also 
on normal thyroid hormone metabolism, delivery of T3 to nuclear receptors and on 
receptor distribution and function. Normal thyroid function, which is essential for 
normal growth, development and the regulation of energy metabolism within cells, 
is dependent on a normally functioning thyroid and liver axis 
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Thyroid metabolism in chronic illness 
In most chronic illness, defects arise in thyroid hormone metabolism, 
resulting in the sick euthyroid syndrome. This is characterized by a normal total T4, 
normal/high free T4, low total T3, low free T3 and an elevated rT3. These changes 
reflect a reduction in type 1 de-iodinase activity, an increase in type 3 de-iodinase 
activity and changes in the plasma concentration of thyroid-binding proteins and 
free fatty acids (which displace thyroid hormones from binding proteins). There are 
also non-thyroidal influences on the hypothalamic-pituitary-thyroid axis, e.g. 
cortisol inhibiting TSH secretion  
It has been suggested that this syndrome may confer a survival advantage, 
which adapts an organism to chronic illness by reducing the basal metabolic rate 
within cells and thereby reducing caloric requirements. These changes in thyroid 
function test results are observed in most of the acute and chronic illnesses.  
Examples of illness include the following:  
• Gastrointestinal diseases  
• Pulmonary diseases  
• Cardiovascular diseases  
• Renal diseases  
9
• Infiltrative and metabolic disorders  
• Inflammatory conditions  
• Myocardial infarction  
• Starvation  
• Sepsis  
• Burns  
• Trauma  
• Surgery  
• Malignancy  
• Bone marrow transplantation 
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Fig I - Euthyroid sick syndrome - Relationship between serum thyroid 
hormone concentrations and severity of nonthyroidal illness 
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Fig II - Euthyroid sick syndrome. Relationship between severity and duration 
of nonthyroidal illness (NTI) and thyroid hormone levels. 
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Pathophysiology 
 
Proposed mechanisms explaining abnormalities in thyroid hormone levels 
• Accuracy of test assays in nonthyroidal illness 
Abnormalities of thyroid function test results might represent test artifacts or 
true abnormalities. According to one proposition, the assays would indicate 
reference range thyroid hormone levels in the blood if appropriate tests were 
applied. 
Inhibition of thyroid hormone binding to thyroid-binding proteins and 
tissues 
Serum thyroid hormone abnormalities are due to inhibition of thyroid 
hormone binding to proteins, thus preventing tests from appropriately reflecting 
free hormone levels. This binding inhibitor can be present both in the serum and in 
body tissues and might inhibit uptake of thyroid hormones by cells or prevent 
binding to nuclear T3 receptors, thus inhibiting the action of the hormone. This 
inhibitor is associated with the nonesterified fatty acid (NEFA) fraction in the 
serum. 
Contrary to this proposition, substantial evidence indicates that, in an in vivo 
state, the levels of binding inhibitors do not reach levels sufficient to influence the 
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circulating levels of free T4, even in patients who are severely ill. Also, some 
studies have failed to demonstrate an existing binding inhibitor. 
• Cytokines:  
Cytokines are thought to play a role in NTI—particularly interleukin (IL)-1, 
IL-6, tumor necrosis factor (TNF)-alpha, and interferon-beta. Cytokines are 
thought to affect the hypothalamus, the pituitary, or other tissues, inhibiting 
production of TSH, thyroid-releasing hormone (TRH), thyroglobulin, T3, and 
thyroid-binding globulins. Cytokines are also thought to decrease the activity of 
type I deiodinase and to decrease the binding capacity of T3 nuclear receptors. 
• Deiodination 
Peripheral deiodination of T4 to T3 is impaired, largely secondary to 
decreased activity of type I deiodinase enzyme, which deiodinates T4 to T3. 
Diminished enzyme activity accounts for decreased deiodination of T4 to T3. 
An alternative explanation is that reduced tissue uptake of T4 secondary to 
deficiency of cytosolic cofactors (e.g, nicotinamide adenine dinucleotide phosphate 
[NADPH], glutathione) results in decreased substrate for type I deiodinase 
enzyme. Type I deiodinase is a selenoprotein; because selenium deficiency is 
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common in critically ill patients, some propose that selenium deficiency may 
contribute to type I deiodinase malfunction.  
Cytokines (e.g, IL-1 beta, TNF-alpha, interferon-gamma) decrease type I 
deiodinase messenger RNA (mRNA) in vitro. Type I deiodinase does not exist in 
the pituitary, where T3 levels are within the reference range, because of enhanced 
local deiodination. This indicates that an enhancement of intrapituitary T4 to T3 
conversion exists due to pituitary-specific and brain-specific type II deiodinase. 
• Inhibition of thyroid-releasing hormone and thyroid-stimulating 
hormone secretion:  
Cytokines, cortisol, and leptin, as well as changes in brain thyroid hormone 
metabolism, affect inhibition and secretion of TRH and TSH. 
• Inhibition of plasma membrane transport of iodothyronines:  
Serum factors, such as bilirubin, NEFA, furanoic acid, hippuric acid, and 
indoxyl sulphate, which are present in various Non Thyroidal Illness (NTIs), have 
been shown to inhibit transport of thyroid hormones. 
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• Thyroxine-binding globulin decrease and desialation:  
T4-binding globulin (TBG) is a member of the serine protease inhibitors. 
Diminished T4 in NTI has been proposed to be due to low TBG caused by protease 
cleavage at inflammatory sites in acute inflammatory conditions. One other 
hypothesis for the cause of disproportionately low serum T4 concentrations in 
patients with NTI is the presence of abnormal serum binding due to desialation of 
TBG. 
The effects of nonthyroidal illness : 
• Triiodothyronine and reverse triiodothyronine  
In healthy people, 20% of T3 production comes from thyroidal secretion and 
80% from peripheral deiodination from T4. In NTI, thyroidal production of T3 is 
normal, but the peripheral production of T3 is decreased. The fractional rate of 
transport of T3 to tissues is unaltered. Production of T3 is decreased, but its 
clearance is unchanged. Production of rT3 is unchanged, while its clearance is 
diminished.  
In rat hepatocytes, rT3 and T4 have been demonstrated to be transported in 
the same mechanism, which implies that a diminished transport of rT3 to the liver 
would accompany inhibition of transport of T4 to the liver (e.g., as in during 
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calorie deprivation). Because the liver is the main site of disposal of T3, this leads 
to a diminished metabolic clearance rate of rT3 and T4.  
Another explanation could be reduced 5'-deiodinase tissue activity, resulting 
in decreased T3 production from T4 and reduced breakdown of rT3. The decreased 
production of T3 during early and late starvation has been explained as either a 
diminished activity of the enzyme (deiodinase) itself or a deficiency of cytosolic 
cofactors, such as NADPH or glutathione.  
Specific deiodinative enzymes, 3 of which have been identified, affect 
deiodination of iodothyronines. Type I deiodinase is present in the liver, kidney, 
and thyroid and affects both 5 and 5' deiodination of T3. Type II deiodinase is 
present in the brain, pituitary, and brown adipose tissue and is active only in 5' 
deiodination. Type III deiodinase is found particularly in the brain, skin, and 
placenta, and it deiodinates iodothyronines at the 5 locations.  
Both type II and type III enzymes are insensitive to 6-propylthiouracil 
(PTU). Alterations of serum thyroid hormone parameters in cases of calorie 
deprivation exhibit similarities to the changes observed in NTI. Fasted animals had 
decreased 5'-deiodinase activity. The activity of type I deiodinase is inhibited by 6-
PTU. Because it is a selenoprotein and selenium deficiency is common in critically 
ill patients, selenium deficiency also may contribute to its malfunction.  
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Cytokines, such as IL-1 beta, TNF-alpha, and interferon-gamma, decrease 
type I deiodinase mRNA in vitro. Infusion of TNF-alpha decreases serum T3 and 
increases rT3. Soluble TNF-alpha, soluble TNF-alpha receptor, soluble IL-2 
receptor antagonist, and IL-6 are inversely correlated with serum T3 levels. The 
elevations of soluble TNF-alpha receptor and IL-6 were independent determinants 
of serum T3 and accounted for 35% and 14%, respectively, of the change in T3.  
These cytokine changes can be concluded to occur concomitantly with 
changes in T3 and may play a pathogenic role through mechanisms that are not 
clearly defined. The increase of endogenous cortisol during illness apparently is 
not involved in inhibition of type I deiodinase.  
Using an adenovirus model in mice hepatocyte primary cultures, it was 
demonstrated that forced expression of steroid receptor co-activator 1 (SRC-1) 
prevented the cytokine induced inhibition of type 1 deiodinase activity, suggesting 
the involvement of  receptor co-activators in the nonthyroidal illness.  
• Free triiodothyronine:  
Most studies have found free T3 hormones to be depressed.  
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• Thyroxine  
The decrease in the T4 binding of TBG has been used as an explanation for the 
low plasma T4 concentration in patients with NTI. The existence of a binding 
inhibitor could explain the observed alterations in T4 and free T4 fraction. TBG 
levels usually are within the reference range in patients with NTI and are 
somewhat lower in critically ill patients with low serum T4. Low TBG levels can 
be explained, according to some proposals, by rapid protease cleavage at 
inflammatory sites, particularly in acute inflammatory states (in which the decrease 
in TBG is too rapid to be accounted for by inhibition of synthesis).  
In patients with NTI, serum T4 concentration has been demonstrated to be 
low because much of the circulating TBG in these patients is desialated. In NTI, 
the fractional rate of T4 transport from serum to tissues is reduced to 50% of the 
reference range value. This decrement in fractional rate of T4 transport is not 
related to the serum levels of total or free T4. Because in illness the reduction in 
the fractional rate of T4 transport from serum to tissues cannot be attributed to 
alterations in serum T4 binding, consider other causes such as an impairment of 
transport into tissues.  
In nonuremic critical illness, it has been demonstrated that elevated 
bilirubin or elevated NEFA and low albumin concentration may be at least 
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partially responsible for the T4 transport inhibition in T3-producing tissues (e.g, 
the liver).  
A correlation exists between the probability of death and the levels of 
total T4. When serum T4 levels drop below 4 mcg/dL, the probability of death 
is about 50%; with serum T4 levels below 2 mcg/dL, the probability of death 
reaches 80%. 
• Free thyroxine  
Evaluating thyroid function in patients with NTI has considerable 
challenges. No consensus exists as to whether free T4 levels are within the 
reference range, low, or high. Free T4 is believed to represent the hormone 
available to tissues. 
 Measurement of total serum T4 has only limited value because nearly all 
(99.97%) of the circulating T4 is bound to TBG, T4-binding prealbumin (TBPA), 
and albumin. The rest of the circulating T4 (0.2-0.03%) is free T4. The circulating 
concentration of these binding proteins is understood to affect the total T4 
concentration without necessarily changing the amount of free T4. Usually, TBG 
levels are within the reference range in patients with NTI and somewhat lower in 
critically ill patients with low serum T4.  
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Decreased concentrations of one or more of the binding proteins would 
explain low levels of total T4 but does not explain a significant increase in free T4 
fraction, which some patients with NTI exhibit.  
Various explanations for the existence of inhibitors of T4 binding have been 
reported. Although low levels of TBPA and albumin may occur in patients with 
NTI, even complete inhibition of T4 binding to these proteins has been 
demonstrated to produce only about a 30% increase in free T4 fraction. Because 
free T4 fraction is increased above this level in many patients, other factors must 
be present.  
The observations of reduced total T4 and free T4 have been explained 
alternatively as either a fall in TBG levels or an inhibition of thyroid hormone 
binding to TBG. Some studies have shown a decrease in the T4 binding of TBG, 
which has been used as an explanation for the low plasma T4 concentration and, 
perhaps, the high free T4 fractions, in patients with NTI. Other studies postulate 
the existence of a binding inhibitor that could explain the observed alterations in 
free T4 fraction.  
The inhibitor also has been demonstrated to interfere with the binding of 
iodothyronines to solid matrices, thus interfering with the T3 resin uptake and 
explaining the low FTI found in patients with NTI. The inhibitor appears to be 
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extractable with ether and was associated with the NEFA fraction in the serum. 
Furthermore, the extracted inhibitor from sera of patients with NTI reduced 
conversion of T4 to T3 in rat liver homogenates. The inhibitor could be extracted 
from extrathyroidal tissues as well.  
The addition of NEFA to normal serum is able to raise the free T4 fraction 
only if total NEFA concentration is higher than 3 millimoles in normal serum, 
representing a NEFA-to-albumin molar ratio greater than 5:1. Because this high 
NEFA-to-albumin ratio is not reached even in severely ill patients, NEFA is 
unlikely to influence the circulating free T4 concentration in vivo. Inhibitors of 
binding were also observed during equilibrium dialysis assay in patients treated 
with heparin. This is due to an in vitro artifact that is not present in vivo.  
Cytokines also can elevate free T4. When TNF-alpha was infused, it was 
observed that free T4 could elevate transiently in association with a significant rise 
in free fatty acids. However, other studies question the role of NEFA inhibition or 
whether any thyroid hormone–binding inhibitor exists at all. 
• Thyroid hormone receptor expression and DNA binding:  
In experimental mouse liver models, infection decreased thyroid hormone 
receptor (TR) expression as well as retinoid X receptor (RXR)–TR DNA binding. 
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TR-alpha and TR-beta protein levels were both decreased when lipopolysaccharide 
was administered, particularly at 16 hours. Lipopolysaccharide exposure was also 
shown to reduce RXR protein levels in the liver.  
• Thyroid-stimulating hormone and thyroid-releasing hormone 
Some patients with Non Thyroidal Illness have slightly elevated serum TSH, 
which is thought to have reduced biological activity. After recovery from severe 
Non Thyroidal Illness, transient elevation of TSH to above-normal limits 
commonly occurs. Some authors interpret this TSH elevation as a sign of recovery 
from a hypothyroid state. Despite the distortion of TSH in some euthyroid patients 
with Non Thyroid Illness, patients with Non Thyroidal Illness who have significant 
elevation of TSH usually have underlying primary hypothyroidism. 
Responsiveness of the pituitary to TRH during Non Thyroidal Illness varies; 
some patients respond normally, while many have a less-than-normal response. 
Normal responsiveness in the presence of low TSH may suggest that a 
hypothalamic abnormality is causing the low TSH and low T4. The down-
regulation at the hypothalamus-pituitary level provides an explanation for the 
decreased sensitivity of TSH secretion to low serum T3 and T4 concentrations in 
patients with Non Thyroidal Illness. A diminution, or loss, of the diurnal rhythm of 
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TSH also occurs, and some studies have produced evidence for a reduction of TSH 
glycosylation with lower TSH bioactivity. 
That TSH is not elevated in the presence of low T4 indicates that the patients 
are not hypothyroid. Diminished release of TRH also is thought perhaps to result in 
low TSH and, thus, low output of thyroid hormones by the thyroid. Low TRH 
mRNA in hypothalamic paraventricular nuclei also has been demonstrated. 
The role of cytokines, especially IL-1 beta, in the activity of the 
hypothalamic-pituitary-adrenal axis is well known. Cytokines also affect TRH in 
rats. IL-1 beta decreases the release of TSH in cultured rat anterior pituitary cells, 
but the role of TNF-alpha on TSH release is disputed. IL-6 decreases TSH 
secretion. In rodents, leptin has been demonstrated as a major mediator of changes 
in hypothalamic-pituitary-thyroid function during fasting. However, TSH secretion 
and thyroid gland function are less affected during Non Thyroidal Illness in 
humans than they are in animals. 
 The role of leptin in patients with Non Thyroidal Illness is unclear. Leptin 
concentrations often are elevated during critical illness and increase acutely in 
response to administration of TNF-alpha or IL-1; however, the leptin increase is 
not related to changes in serum T3 and T4 concentrations. 
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Thyroid abnormalities in liver disease 
In the different types of liver disease, similar processes may occur to those 
seen in the sick euthyroid syndrome, but in addition a number of changes specific 
to the type or stage of liver disease is also found. 
 
Cirrhosis 
The most consistent thyroid hormone profile in patients with cirrhosis are a 
low total and free T3 and an elevated rT3, similar changes to those in the sick 
euthyroid syndrome, probably reflecting a reduced deiodinase type 1 activity, 
resulting in reduced conversion of T4 to T3. This results in an increase in 
conversion of T4 to rT3 by the deiodanase type 3 system, and an increase in the rT3 
to T3 ratio.  
The plasma T3:rT3 ratio has a negative correlation with the severity of 
cirrhosis when assessed in non-alcoholic cirrhotics. Since T3 and rT3 bind to the 
same plasma proteins, the T3/rT3 ratio provides a parameter of liver function that is 
largely independent of protein binding. Both the T3/rT3 ratio and free T3 levels in 
plasma thus provide a correlate of liver function in cirrhosis, and are of prognostic 
value, albeit seldom used. 
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The low total and free T3 levels may be regarded as an adaptive hypothyroid 
state that serves to reduce the basal metabolic rate within hepatocytes and preserve 
liver function and total body protein stores. Indeed, a recent study in cirrhotic 
patients showed that the onset of hypothyroidism from intrinsic thyroid disease of 
various etiologies during cirrhosis resulted in a biochemical improvement in liver 
function (e.g. coagulation profiles) as compared to cirrhotic controls. 
Hypothyroidism has also been associated with lesser degrees of decompensation in 
cirrhosis. Controlled induction of hypothyroidism might therefore be beneficial in 
cirrhotic patients, but further studies are required to test this hypothesis.  
Acute hepatitis and acute liver failure 
         In acute hepatitis of mild or moderate severity, patients have elevated serum 
levels of total T4, due to increased thyroid-binding globulin, which is synthesized 
as an acute-phase reactant, but normal levels of free T4. In more severe cases with 
impending liver failure, the data is variable, and low total T4 levels may reflect 
reduced hepatocellular synthesis of thyroid-binding globulin. 
 Serum T3 levels are extremely variable, but the free T3:T4 ratio correlates 
negatively with the severity of the liver disease and has prognostic value. Again 
this probably reflects diminished type 1 deiodinase activity, resulting in a reduced 
conversion of T4 to T3; in general, however, these patients are clinically euthyroid. 
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Some series have described patients with acute hepatic failure (especially viral 
hepatitis) as having goiters that resolved with improvement in liver function.  
Specific forms of chronic liver disease 
        In patients with chronic hepatitis associated with primary biliary cirrhosis 
(PBC) or chronic autoimmune hepatitis, there is an increased prevalence of 
autoimmune thyroid disease. Thus abnormalities may arise from thyroid gland 
dysfunction or as a consequence of the liver disease. Autoimmune hypothyroidism 
is a prominent feature in PBC, occurring in 10–25% of patients. There is often an 
increase in total T4 in PBC, due to an increase in thyroid-binding globulin levels, 
and this may mask hypothyroidism, emphasizing the need to perform a free T4 and 
TSH assay. Anti-thyroid microsomal antibodies are common in PBC (34%), as are 
anti-thyroglobulin antibodies (20%).Thyroid dysfunction may precede or follow 
the diagnosis of PBC. In autoimmune hepatitis, both Grave's disease (6%) and 
autoimmune hypothyroidism (12%) are relatively common. Primary sclerosing 
cholangitis is associated with an increased incidence of Hashimoto's thyroiditis, 
Graves's disease and Riedel's thyroiditis. 
In patients with chronic hepatitis who do not have co-existing autoimmune 
liver and thyroid disease, total T4, total T3, thyroxine-binding globulin levels are 
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often increased, but TSH and free T4 levels are usually normal, and patients are 
clinically euthyroid. 
Currently the treatment of viral hepatitis with alpha interferon has added 
another dimension to the abnormalities of thyroid function seen in chronic liver 
diseases. In different studies assessing patients treated with alpha interferon for 
hepatitis C, 2.5–10% developed thyroid dysfunction, with both thyrotoxicosis (due 
to acute thyroiditis) and hypothyroidism being observed. Although the reason is not 
altogether clear, the induction of an autoimmune reaction has been postulated, 
resulting in the development of anti-thyroid and anti-thyrotrophin receptor 
antibodies. However, a distinct effect on intrathyroidal organification of iodine has 
also been suggested.  
The risk factors for developing thyroid dysfunction with alpha interferon 
(which may persist after discontinuation of the drug) are female sex, underlying 
malignancy, high doses of long duration, combination immunotherapy (especially 
Il-2), and the presence of anti-thyroid peroxidase antibodies prior to commencing 
treatment.  
It should be noted that interferon therapy causes weakness and muscle 
aching, and in this setting the myopathy of hypothyroidism may be missed. It is 
therefore recommended that thyroid function tests (including thyroid antibodies) 
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are performed prior to therapy, and subsequently monitored at 3–6 month intervals 
during interferon therapy. 
Liver abnormalities in thyroid disease 
Hypothyroidism 
        Hypothyroidism may have features that mimic liver disease (pseudo-liver 
disease): examples include myalgias, fatigue and muscle cramps in the presence of 
an elevated aspartate aminotransferase from a myopathy, coma associated with 
hyperammonaemia in myxoedema coma, and myxoedema ascites. 
Hyperthyroidism 
Liver injury caused by thyrotoxicosis is relatively common, and can be 
conveniently divided into hepatitic or cholestatic types. 
 Hepatitic injury 
An increase in the aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) is seen, although the majority of these patients showed no 
other clinical or biochemical features of liver impairment. The mechanism of injury 
appears to be relative hypoxia in the perivenular regions, due to an increase in 
hepatic oxygen demand without an appropriate increase in hepatic blood flow 
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Cholestatic injury 
       An elevated serum alkaline phosphatase is seen in of patients with 
thyrotoxicosis   
Anti thyroid drugs                                                                                                   
Increased serum levels of aspartate aminotransferase and alanine aminotransferase 
occur in about 30% of patients treated with propylthiouracil. The rise in AST 
appears to be dose-related, so that AST and ALT levels are highest during the first 
few weeks of treatment, falling rapidly with a dose reduction 
Other thyroid and liver interactions 
Physiological 
       The liver is the major site for cholesterol and triglyceride metabolism, and the 
thyroid hormones play an integral part in hepatic lipid homeostasis. Thyroid 
hormones increase the expression of LDL receptors on the hepatocytes, and 
increase the activity of lipid-lowering liver enzymes, resulting in a reduction in 
low-density lipoprotein levels. Thyroid hormones also increase the expression of 
apolipoprotein A1, a major component of high-density lipoprotein. 
Pathological 
       A number of disease processes and drugs can affect both the liver and the 
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thyroid gland simultaneously. The autoimmune diseases, organ infiltration such as 
malignancy, amyloid, or in secondary haemachromatosis, drugs like amiodarone, 
mefloquine, carbamazepine 
        Recent work investigating the use of tri-iodothyronine as a hepatic growth 
factor has shown it to be a primary mitogen for the liver in animal models (i.e. it 
induces hepatocyte proliferation and increases liver mass when administered at 
high doses in the absence of hepatic injury). The ability to increase liver mass in the 
absence of liver damage, and to enhance proliferation during compensatory 
hyperplasia after liver damage, could be therapeutically valuable if applicable to 
man. More generally, the ability to manipulate liver cell proliferation in vivo may 
be helpful in designing cell transplantation and gene therapy approaches to liver 
diseases. 
Diagnosis of Thyroid Disease in Euthyroid Sick Syndrome 
During starvation and mild illness, a low T3 concentration, or low T3 and 
low T4 levels in a patient with a low-normal TSH level, is the hallmark of 
euthyroid sick syndrome. However, nonthyroidal illness may present with a 
spectrum of abnormalities in thyroid function that may complicate the diagnosis of 
euthyroid sick syndrome. 
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 Low T3 levels with normal T4 and TSH levels are the most common 
abnormality seen in euthyroid sick syndrome. Serum TSH levels are typically 
normal or reduced. The TSH levels are normal/subnormal in approximately 80% of 
patients, and are markedly suppressed (<0.1 µU/mL) in <10% of patients. Thus, in 
a patient with a systemic illness, low T4 and T3 levels and a normal or low-normal 
TSH level most likely indicate euthyroid sick syndrome.  
In the recovery phase of illness, mild elevation of TSH levels can be 
observed; however, serum level of TSH >30 µU/mL is rarely seen in euthyroid 
sick syndrome and strongly suggests the diagnosis of primary hypothyroidism. 
Levels of TSH above 20 µU/mL are found in <3% of patients with nonthyroidal 
illness.  
Differentiation between secondary hypothyroidism (pituitary or 
hypothalamic) and euthyroid sick syndrome may be difficult. Both conditions 
present with decreased levels of total T4, T3, and TSH. Many chronically ill 
patients are edematous, have associated infections, or have cardiopulmonary 
disorders that could easily mask evidence of thyroid disorders. Additional tests, 
including obtaining basal and/or stimulated cortisol, serum gonadotropin, and 
prolactin levels may be of help in such cases. If the serum cortisol level is normal 
or elevated, as would be expected in stressful situations, euthyroid sick syndrome 
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is probably the cause, rather than pituitary dysfunction. If serum cortisol and 
gonadotropin levels are low, pituitary dysfunction should be suspected, and 
treatment with corticosteroids and thyroid hormone supplementation is indicated. 
 In some instances, it may be difficult to exclude hyperthyroid patients, who 
may present with suppressed TSH levels and normal T4 and T3 levels in the 
presence of infection or other catabolic illness. Hyperthyroid patients who are 
chronically ill or malnourished may have hypoproteinemia and low levels of TBG 
that lower their T4 and T3 levels. In such patients, an elevated free-T4 level and a 
low or undetectable TSH level will confirm the diagnosis of hyperthyroidism. A 
previous history of thyroid illness, a history of external radiation, or the presence 
of goiter and/or a midline neck scar may indicate a primary thyroid condition. 
Certain pharmacologic agents may alter the serum concentration of thyroid 
hormones and should be taken into account in the evaluation of patients with 
nonthyroidal illness. The concentrations of total T3, free-T4, and TSH are reduced 
in patients treated with dopamine or corticosteroids, due to suppression of pituitary 
TSH release and/or inhibition of conversion of T4 to T3. Levels of total and free-T4 
may be increased in patients treated with amiodarone or iodinated radiocontrast 
agents. Intravenous or subcutaneous heparin therapy may result in increased free-
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T4 levels, due to in vitro interference with the laboratory assay; however, most 
such patients remain clinically euthyroid and have normal total T4 and TSH levels. 
It is not prudent to rely solely on a single thyroid test in the evaluation of 
thyroid function of patients with critical illness. In such patients, a careful 
assessment of multiple tests may be needed to distinguish patients with euthyroid 
sick syndrome. In many instances, it is reasonable to delay the final diagnosis for 
several days to weeks, or after recovery from the acute illness, to determine the 
correct thyroid status. 
Faber J et al kinetic studies of thyroxine, 3,5,3'-triiodothyronine, 3,3,5'-
triiodothyronine, 3',5'-diiodothyronine, 3,3'-diiodothyronine, and 3'-
monoiodothyronine in patients with liver cirrhosis found that serum T4, T3, and 
3,3'-T2 levels were reduced in patients with liver cirrhosis, whereas serum rT3 and 
3',5'-T2 levels were increased. Serum 3'-T1 levels were unaltered. 
Chopra IJ et al showed alterations in circulating thyroid hormones and 
thyrotropin in hepatic cirrhosis: evidence for euthyroidism despite subnormal 
serum triiodothyronine 
 
 Nomura S et al showed reduced peripheral conversion of thyroxine to 
triiodothyronine in patients with hepatic cirrhosis. 
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Bermudez F et al observed a high incidence of decreased serum 
triiodothyronine concentration in patients with nonthyroidal disease. 
 
Bianchi GP et al measured Thyroid volume at ultrasound in 118 consecutive 
patients with cirrhosis of different etiology and 48 healthy subjects matched for 
age and sex. No subjects had evidence of overt thyroid disease. The mean volume 
was increased by 17% (from 16.0 [SD 5.2] ml in controls to 18.8 [7.6] in cirrhosis; 
P less than 0.025), and thyroid enlargement (antero-posterior diameter greater than 
20 mm) was present in 38% of cases, in the presence of hormone values indicative 
of low-T3 syndrome. No significant differences in thyroid gland size were 
observed in relation to the extent of liver dysfunction or to the etiology of liver 
disease. The prevalence of thyroid nodules was similar in controls and in patients 
with cirrhosis   
 
M Borzio et al studied thyroid function tests in chronic liver disease and 
confirmed the existence of several abnormalities of thyroid function tests in 
patients with chronic liver disease, although showing that euthyroidism is almost 
always maintained, probably as a result of low-normal FT3 and high-normal FT4. 
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L'age M, Meinhold H, Wenzel KW, Schleusener H measured Serum levels 
of TSH, thyroxine-binding globulin (TBG), T4, T3 and reverse T3 (rT3) in 36 
patients with fatty liver disease, 11 patients with chronic persistent hepatitis, 17 
patients with chronic active hepatitis, and 29 patients with liver cirrhosis. TBG was 
significantly above normal levels in both groups of chronic hepatitis, the slight 
concomitant T4 and T3 increase was significant only for T4 in chronic persistent 
hepatitis. A significant decrease in T4 and T3 concentration was found in fatty 
liver disease and in hepatic cirrhosis. A shift in T4 conversion to rT3 could 
exclusively be demonstrated for the group of hepatic cirrhosis, reflected by a 
significant increase in rT3 
 
Hitomi TAKAHASHI et al studies on changes of Thyroid Hormones in 
Various Liver Diseases showed usefulness of free Thyroid Hormones as Liver 
Function Test. 
R. MALIK and H. HODGSON studied the relationship between the thyroid 
gland and the liver and observed that thyroxine and tri-iodothyronine hormones 
modulate hepatic function; the liver in turn metabolizes the thyroid hormones and 
regulates their systemic endocrine effects. Thyroid dysfunction may perturb liver 
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function, liver disease modulates thyroid hormone metabolism, and a variety of 
systemic diseases affect both organs. 
 
 Van Thiel DH et al assayed T4, T3, rT3 and TSH in 134 adult patients 
evaluated and accepted as potential liver transplant candidates at the University of 
Pittsburgh from March, 1981 to December, 1983. The subsequent course of these 
patients was evaluated with respect to the levels of these hormones obtained at the 
time of acceptance for transplantation. T4 levels were increased significantly while 
their T3 levels were reduced (both p less than 0.01) in those who survived and 
were discharged home as compared to either those who died waiting to be 
transplanted or died following the procedure. As a result, the ratio of T3/T4 was 
reduced markedly (p less than 0.01) in those who were transplanted and survived 
as compared to those not transplanted or dying following transplantation  
Van Steenbergen W, et al studied thyroid hormones and the hepatic handling 
of bilirubin and effects of hypothyroidism and hyperthyroidism on the hepatic 
transport of bilirubin 
 
 Malik R et al studied the effects of thyroid hormone on the liver and 
suggested  a novel approach to increase liver mass. 
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MATERIALS 
               AND  
 METHODS 
 
 
 
 
 
             MATERIALS AND METHODS 
 
SETTING : 40 patients with symptoms, signs with biochemical and radiological 
evidence of chronic liver disease who were admitted in the general medical ward 
of Government Stanley Medical College and Hospital were enrolled for this study 
after prior written and informed consent 
The age group of these patients ranged from 25 years to 75 years 
PERIOD OF STUDY : JANUARY 2009 – OCTOBER 2009 
ETHICAL COMMITTEE APPROVAL : The present study was approved by 
the ethical committee 
CONSENT : Study group thus identified was informed about the nature of the 
study and willing participants were included in the study after getting written 
informed consent 
SAMPLE POPULATION : 80 Patients – 40 cases and 40 controls 
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Out of these 40 cases, 30 patients were males and 10 patients were females. 
Out of the 30 males, 25 had had alcohol related chronic liver disease and out 
of the remaining 5, 2 patients had Wilson’s disease, 3 had post viral chronic liver 
disease. 
Out of the 10 females, 5 had post viral chronic liver disease, 2 patients had 
alcoholic liver disease and remaining had cryptogenic cirrhosis. 
All subjects were hospitalized because of signs and symptoms of 
decompensated liver disease. 
INCLUSION CRITERIA : 
• Patients with symptoms, signs with biochemical and radiological evidence 
of chronic liver disease 
• Those patients willing to participate in the study  
EXCLUSION CRITERIA 
• Patients with upper gastro intestinal bleeding,  
• Patients with acute hepatic encephalopathy  
• Patients with renal failure 
• Patients on thyroid medications already 
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Our patients did not show clinical signs or symptoms of thyroid dysfunction 
and did not receive medications that might have affected the radio immuno assay 
performed in the study. 
As a control group 40 healthy subjects (30 men; 10 women) aged 25 – 75 
years, matched for their age, sex was investigated. 
All the patients were assessed for the duration of chronic liver disease and 
were also asked about past history of jaundice, blood transfusion, marital and 
sexual history and duration of alcoholism (if present).  
Physical examination in search of stigmata of chronic liver disease was 
routinely done in all patients. Ophthalmologic examination was done to look for 
KF ring. Detailed cardiovascular and neurological examination was done. 
Each patients’ complete history was recorded in a proforma. Every patient 
was investigated in the following order after the completion of physical 
examination 
Blood: 
Hemoglobin 
Total WBC count; Differential count 
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ESR 
Random blood sugar 
Blood urea 
Serum creatinine 
Liver function tests 
Ultrasound abdomen and pelvis 
Portal vein Doppler 
Serum T3, T4, TSH FT3, FT4 
Serum T3, T4 was determined by standard radio immuno assay. Serum free 
T3 (FT3) and free T4 (FT4) were measured by direct radio immuno assay. 
Patients were deferred liver biopsy owing to clinical conditions or 
coagulation abnormalities. 
The normal ranges for thyroid functions in our laboratory are as follows: 
T3 : 80 – 200 ng / dl 
T4 : 4.5 – 12 mcg / dl 
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FT3 : 2.7 – 6.6 pg / ml 
FT4 : 6.3 – 16.4 pg / ml 
Blood samples were also collected from 40 control subjects for thyroid and 
liver function analysis. 
All the vital data and blood reports for the study and control group were 
entered into a master chart and analysed 
The statistical analysis was carried out using unpaired t test. Data were 
expressed with respect to ‘p’ value, mean and standard deviation. 
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RESULTS 
 
 
 
 
 
 
 
 
RESULTS 
 
Total no. of patients in the study group : 40 
Male                                                       : 30 
Female                                                   : 10 
 
Total no. of controls in the study group : 40 
Male                                                       : 30 
Female                                                   : 10 
 
Table I 
Age wise distribution of patients in the study group  
 
 
     
Age group (in years) Male Female 
25 - 35 2 3 
35 - 45 3 5 
45 - 55 20 1 
55 - 75 5 1 
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SCATTER DIAGRAM SHOWING SERUM T4 vs.T3 
 IN INDIVIDUAL PATIENTS WITH CHRONIC LIVER DISEASE 
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                           SERUM T3 VALUES IN PATIENTS WITH  
CHRONIC LIVER DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOW(42%)
NORMAL(58%)
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SERUM T4 VALUES IN PATIENTS WITH 
CHRONIC LIVER DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOW(12.5%)
NORMAL(87.5%)
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Table II 
 
Clinical diagnosis and etiological factors: 
 
  
No. of  
Patients 
 
 
Alcoholic 
 
Post viral 
 
Others 
 
Male 
 
30 
 
25 
 
3 
 
2 
 
Female 
 
10 
 
2 
 
 
5 
 
3 
 
 
 
Table III 
 
Biochemical indices of liver function of patients: 
 
SGPT BILIRUBIN ALBUMIN PROTHROMBIN 
TIME 
 
 
40 ± 9 
 
 
2 ± 0.6 
 
 
2.7 ± 0.1 
 
 
35 ± 5 
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 Table IV 
 
Indices of thyroid function in patients with chronic liver disease and  
sex and age matched healthy controls (mean values with standard deviation) 
 
  
T3(ng/dl) 
 
T4(mcg/dl)
 
FT3(pg/ml)
 
 
FT4(pg/ml) 
 
TSH(m U/ml) 
 
Cases 
 
 
84.1 ± 9.6 
 
6.2 ± 1.3 
 
3.7 ± 0.9 
 
11.5 ± 2.6 
 
3.2 ± 0.9 
 
Controls 
 
 
92.7 ± 8.1 
 
7.1 ± 1.2 
 
4.2 ± 0.7 
 
12.9 ± 2.4 
 
3.7 ± 0.9 
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INTERPRETATION OF THE VALUES : 
 
• Patients with chronic liver disease showed significantly reduced serum 
levels of T3. 
 
•  4 patients had low normal levels of FT3.  
 
• 5 patients had low T4 values. 
 
• All patients had normal FT4 and TSH values. 
 
• Simple correlation analysis showed that the serum T3 concentration 
significantly correlated with serum bilirubin, albumin and prothrombin in 
chronic liver disease but not with transaminases. 
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STATISTICAL ANALYSIS : 
 
T3 : 
• Out of 40 cases, T3 value ranged from a minimum of 76 to maximum of 
112.2 ng/dl  
•  Mean value of T3 among cases was 84.1 ng/dl 
• Standard deviation of T3 among cases was ± 9.6  
• Out of 40 controls, T3 value ranged from a minimum of 82 to maximum of 
118.0 ng/dl  
•  Mean value of T3 among controls was 92.7 ng/dl 
• Standard deviation of T3 among cases was ± 8.1 
‘p’ value calculated for T3 is <0.001 which is statistically significant. 
 
T4 : 
• Out of 40 cases, T4 value ranged from a minimum of 3.6 to maximum of 9.7 
mcg/dl  
•  Mean value of T4 among cases was 6.2 mcg/dl 
• Standard deviation of T4 among cases was ± 1.3 
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• Out of 40 controls, T4 value ranged from a minimum of 4.6 to maximum of 
10.2 mcg /dl  
•  Mean value of T4 among controls was 7.1 mcg / dl 
• Standard deviation of T4 among cases was ± 1.2 
‘p’ value calculated for T4 is 0.0013 which is statistically significant. 
 
Free T3: 
• Out of 40 cases, FT3 value ranged from a minimum of 2.55 to maximum of 
6.1 pg/ml  
•  Mean value of FT3 among cases was 3.7pg/ml 
• Standard deviation of FT3 among cases was ± 0.9  
• Out of 40 controls, FT3 value ranged from a minimum of 2.8 to maximum 
of 6.4 pg/ml 
•  Mean value of FT3 among controls was 4.2 pg/ml 
• Standard deviation of FT3 among cases was ± 0.7 
• ‘p’ value calculated for FT3 is 0.0042 which is statistically significant 
 
FT4 : 
• Out of 40 cases, FT4 value ranged from a minimum of 6.3 to maximum of 
16.4 pg/ml 
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•  Mean value of FT4 among cases was 11.5 pg/ml 
• Standard deviation of FT4 among cases was ± 2.6  
• Out of 40 controls, FT4 value ranged from a minimum of 8.75 to maximum 
of 16.4 pg/ml 
•  Mean value of FT4 among controls was 12.9 pg/ml 
• Standard deviation of FT4 among cases was ± 2.4 
• ‘p’ value calculated for FT4 is 0.008 which is statistically significant 
 
TSH : 
• Out of 40 cases, TSH value ranged from a minimum of 1.73 to maximum of 
5.4 mU/ml  
•  Mean value of TSH among cases was 3.2 mU/ml 
• Standard deviation of TSH among cases was ± 0.9 
• Out of 40 controls, TSH value ranged from a minimum of 2.0 to maximum 
of 5.5 mU /ml 
•  Mean value of TSH among controls was 3.7 mU/ml 
• Standard deviation of T4 among cases was ± 0.9 
‘p’ value calculated for TSH is 0.014 which is statistically significant. 
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DISCUSSION 
 
 
 
 
 
 
DISCUSSION 
 
 
 The existence of low T3 syndrome i.e., low total T3 with normal total T4 in 
the absence of clinical hypothyroidism has been frequently reported in patients 
with chronic liver disease and it has been shown to depend on impaired liver 
conversion of T4 to T3. 
  
The liver plays an important role in thyroid hormone metabolism being 
involved in their conjugation, excretion, peripheral deiodination and in the 
synthesis of thyroid binding globulin. 
 
This study confirms a highly significant decrease in T3 serum concentration 
in liver disease, the lowest values correlate with sever disease 
 
In a large group of alcoholic patients Israel et al reported a significant 
correlation between serum T3 concentration and severity of liver dysfunction as 
well as progressive T3 increase in those subjects eventually displaying favourable 
outcome suggesting that T3 concentration in patients with advanced liver disease 
may be considered as helpful prognostic indicator. 
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This study found a good correlation between T3 concentration and serum 
albumin, bilirubin, prothrombin time while no correlation has been found with 
hepatic inflammatory indices like transaminases 
 
This result suggests that T3 concentration should be considered as a 
sensitive index of hepatic function in liver disease. 
 
Green et al found normal FT3 and FT4 in a small group of cirrhotic patients 
while low FT4 and normal FT3 concentrations were present in alcoholic fatty liver. 
 
Many studies performed on equilibrium dialysis, however showed decreased 
FT3 and normal or frequently increased FT4 concentration. These findings are 
confirmed by present study with direct radioimmunoassay of FT3 and FT4 in 
chronic liver disease.  
  
These data suggest that in a patient with chronic liver disease, euthyroidism 
is maintained by a subtle equilibrium between low FT3 and increased FT4 
concentrations 
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CONCLUSION 
 
 
 
CONCLUSION 
 
• The present investigation in which thyroid function has been evaluated with 
all the clinically available indices, confirms the existence of several 
abnormalities in thyroid function test in chronic liver disease, although 
showing  that euthyroidism is maintained virtually in all patients, probably 
as a result of low normal FT3 and high normal FT4. 
 
• Furthermore serum T3 concentration appear to parallel the severity of liver 
dysfunction  
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ANNEXURES 
 
 
 
PROFORMA 
 
Name    Age    Sex 
 
O.P/ I.P No : 
 
Occupation : 
 
Address : 
 
Per capita income : 
 
Presenting complaints : 
H/o present illness : 
 onset 
duration 
course 
H/o suggestive of hypo- or hyperthyroidism 
H/o associated symptoms 
Past history : 
 H/o any jaundice/blood transfusions 
Family history : 
Personal history : 
Diet : 
 Sleep : 
 Appetite : 
 Bowel & bladder  habits : 
 Habits : smoking / alcoholism 
           H/o high risk behaviour 
Menstrual history (in females): 
Menarche/menopause; cycles; flow 
Obstetric history (in females): 
 H/o pregnancy / lactation 
 H/o intake of OCPs 
Treatment history : 
 H/o previous treatment / surgeries 
 
 
 
General Physical Examination : 
Consciousness; orientation  
Built & nourishment 
 Febrile/afebrile 
Pallor / cyanosis / clubbing / icterus / lymphadenopathy / pedal edema 
 
Pulse rate :    Peripheral pulses : 
 
Blood pressure : 
 
Respiratory rate : 
 
Temperature : 
 
          Thyroid examination : 
 
Systemic Examination : 
 
 Cardiovascular system : 
 
 Respiratory system : 
 
 Abdomen (including genital and per rectal examination): 
 
 Central nervous system : 
 
 
 
 
 
DIAGNOSIS : 
 
 
 
 
 
 
 
INVESTIGATIONS : 
 
 
• Hb%, TC, DC, ESR, Platelet 
 
• Urine – albumin, sugar, deposits 
• Blood urea 
• Serum creatinine 
• Liver function tests 
• Coagulation profile 
• Ultrasound abdomen and pelvis 
• Portal vein Doppler 
• Serum T3, T4, TSH FT3, FT4 
• Portal vein Doppler  
 
• Ultrasonogram abdomen & pelvis 
 
• CT abdomen (as required) 
 
 
 
 
 
 
 
 
 
 
 
S.No Age Sex T3 T4 FT3 FT4 TSH Bilirubin Albumin PT SGPT
1 27 M 79.2 4.2 2.55 6.7 1.73 3.3 2.1 45 46
2 30 M 81.4 4.5 3.8 7.9 2.5 2.1 2.8 56 62
3 40 M 79 5.2 3.81 6.9 2.6 2 2.4 36 58
4 37 M 90.6 6 5.6 12.2 4.6 1.7 3.1 44 51
5 42 M 76.5 3.7 2.7 9 3.11 3.2 2 46 48
6 48 M 83 4.8 3.82 7.7 2.81 1.8 1.9 52 59
7 47 M 82.4 4 3.8 10.7 3.4 1.6 2.1 55 47
8 55 M 110.6 7.3 6.1 16.4 3.5 1.9 2.4 51 65
9 52 M 81.4 6.1 3.2 12 5 2.3 3 49 40
10 50 M 98.2 7 6 14 5.2 2 2.7 57 54
11 49 M 78 4.9 2.9 6.3 2.8 2.6 2 52 57
12 50 M 80 3.9 3.8 12.2 2.7 1.3 2.6 50 46
13 52 M 77 3.6 2.62 11.8 3.2 3 2.8 42 62
14 47 M 76 5.4 2.6 12.4 3.51 3.8 3.3 53 58
15 45 M 100.4 8.1 4.4 10.6 5.4 1.7 3.1 50 49
16 54 M 84 6.3 3.1 8.6 3.27 3.2 2.7 57 47
17 51 M 79 5.7 2.7 8.4 2.9 2.7 2.2 48 40
18 48 M 84.8 6.5 3.1 10.8 4.1 3.3 2.5 44 72
19 46 M 78.6 5.8 2.82 11.9 2.84 3.2 3 52 49
20 50 M 77.8 5.8 4 11.72 2.72 2.9 2.9 41 59  
MASTER CHART FOR THE STUDY GROUP - CASES
S.No Age Sex T3 T4 FT3 FT4 TSH Bilirubin Albumin PT SGPT
21 55 M 81.6 7.5 3.15 13.2 3.31 2.2 2.1 44 35
22 48 M 82.4 6.4 3.8 13 3.2 2 2.4 47 45
23 60 M 83.6 7.4 3.9 10.62 2.7 2.4 2.5 43 67
24 72 M 78.2 6.2 3.2 8 3 2.1 2 39 56
25 52 M 79.3 6.4 3.12 10.2 3.1 3.4 2.2 52 49
26 70 M 112.2 9.7 4.8 15.2 5.3 1.9 3.2 56 39
27 54 M 114 8.2 4.45 15 3.5 2 3 42 58
28 48 M 84.2 7.2 3.1 11.9 3.1 2.2 2 40 49
29 53 M 76 6 3 7.2 1.82 2.7 2.8 36 40
30 59 M 77.9 7.1 4.5 10 2 3 1.9 47 50
31 32 F 85.7 6.3 3.9 15.9 1.96 1.7 2 41 62
32 42 F 77.4 6.1 2.9 10.9 1.89 2.9 3 34 49
33 48 F 82.6 6.6 4.2 12.6 2.5 2.3 2.8 39 47
34 56 F 79.9 6.2 2.8 12.3 2.5 2.5 3 30 54
35 34 F 78.7 7 2.91 12.4 2 2.6 2.7 43 55
36 38 F 86.2 6.7 4.1 15.8 3.41 1.9 2.3 45 50
37 30 F 78.2 6.8 2.94 10.8 2.7 3 2.6 47 43
38 45 F 82.8 6.9 3.95 14 3.38 1.8 2.9 34 45
39 39 F 83.4 6.8 3.8 13.4 3.3 3.2 2.8 39 58
40 35 F 84 7.2 2.6 13.2 3.36 2.6 3 34 57  
 
 
 
MASTER CHART FOR THE STUDY GROUP - CASES
 
S.No Age Sex T3 T4 FT3 FT4 TSH Bilirubin Albumin PT SGPT
1 28 M 84 5.4 3.95 14.4 2.4 0.9 4.7 21 23
2 32 M 90.2 8.2 3.8 13.7 3.2 1.1 3.2 24 19
3 39 M 94 8.2 3.82 12.4 4.2 1.2 3.3 30 16
4 37 M 96.9 7.3 3.9 8.9 4 0.9 4.2 30 21
5 40 M 97.2 7.9 4 15.5 3.2 1.1 3 25 30
6 46 M 100.4 9.4 4.41 10.8 4.1 0.7 4 28 31
7 46 M 92.6 5.4 5 15 5.42 1.2 3.7 17 32
8 54 M 94.1 7.4 3.4 10.2 5.5 0.7 3.6 15 34
9 51 M 83 8.4 6.4 9.8 4.32 0.9 4.1 19 23
10 52 M 94.2 8.7 4.2 16 3.9 1.3 3.2 21 19
11 47 M 97.6 6 4.9 10.2 3.2 1.1 3.9 24 39
12 49 M 104.2 7.2 4.3 9.7 3.14 0.8 4.9 22 15
13 52 M 84.3 6.4 3.7 15 3.72 1 4 29 28
14 45 M 86.2 7.5 4.23 9.9 5.48 1.2 4.2 30 19
15 47 M 94.7 7.2 3.7 16.24 4.8 0.7 4.8 24 36
16 52 M 91.8 8.1 4.6 12 2 0.8 4.1 30 17
17 54 M 108.4 5.8 4.2 9.7 2.62 1.1 3.7 28 35
18 49 M 93.8 7.4 4.29 12.5 3.4 0.9 3.9 30 20
19 47 M 88.4 6.9 4.28 12.4 3 0.9 5 23 27
20 50 M 92.2 6.3 4.2 15.2 3.75 1.2 4 29 28  
MASTER CHART FOR THE STUDY GROUP - CONTROLS
S.No Age Sex T3 T4 FT3 FT4 TSH Bilirubin Albumin PT SGPT
21 54 M 83.4 4.6 4.4 14.4 2.4 0.8 4 20 19
22 49 M 98.2 7 3.8 12 3 1 3.7 23 20
23 58 M 110.4 5.2 5 15.4 2.3 1.2 3.8 28 17
24 70 M 82 5.9 4.96 13.4 4.3 0.7 4.2 30 15
25 52 M 87.2 6.8 2.9 11.7 4.3 1.1 3 21 30
26 69 M 99.2 7 3.81 12.5 5.4 0.6 4.5 26 34
27 55 M 118 5.4 4.2 10 3.8 1.2 3 17 23
28 48 M 99.2 7.5 4.4 16.4 3.2 0.7 3.6 16 34
29 51 M 87.2 7.7 5.4 12.52 2.72 0.9 4.3 15 37
30 58 M 88 5.8 2.8 12.2 3.9 1 4.1 18 31
31 30 F 89.3 7.7 4.31 15.5 4.15 1.1 3.9 20 39
32 42 F 98.2 5.2 3.9 13.6 5.4 0.8 4.7 22 42
33 47 F 93.6 10.2 4.1 11.9 3.2 0.9 4.9 27 28
34 56 F 86.2 5 5.2 16.2 3.4 1.2 4.2 30 27
35 35 F 91.4 7.2 4.32 10.1 2.5 0.9 4 23 36
36 38 F 83.2 8.9 4.26 13.8 4 0.8 4.1 30 31
37 32 F 90 7.3 3.6 16.4 2.6 1 5 26 35
38 44 F 84 8 3.5 8.75 3 0.7 4.8 32 28
39 38 F 96.2 6.9 4.5 15 3.1 0.9 4.2 27 22
40 36 F 92.6 7.2 4.2 13.7 4.14 1.1 4.6 21 30  
MASTER CHART FOR THE STUDY GROUP - CONTROLS
